Duo Li - Publications

A novel biguanide-derivative promotes NEDD4-mediated FGFR1 ubiquitination through BMI1 to overcome osimertinib resistance in NSCLC.

Journal: Cancer biology & medicine

Published: September 11, 2025

Novel combination therapy with phenformin enhances the effects of lenvatinib in hepatocellular carcinoma via AMPK-mediated PDGFRβ degradation.

Journal: Cancer cell international

Published: March 12, 2025

SMK-002 inhibits the growth of bladder cancer cells and increases their sensitivity to Osimertinib via enhancing epidermal growth factor receptor degradation.

Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Published: March 03, 2025

Repression of EGFR by new biguanide 4C potentiated ovarian cancer to PARP inhibitors through down-regulation of BRCA2 and Rad51.

Journal: Cell death & disease

Published: February 08, 2025

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.

Journal: Frontiers in oncology

Published: May 30, 2024

Progress in antitumor mechanisms and applications of phenformin (Review).

Journal: Oncology reports

Published: May 16, 2024

Sotorasib inhibits ubiquitination degradation of TXNIP and suppresses glucose metabolism in KRASG12C mutant bladder cancer.

Journal: American journal of cancer research

Published: March 07, 2024

A label-free activatable biosensor for in situ detection of exosomal microRNAs based on DNA-AgNCs and hairpin type nucleic acid probes.

Journal: Analytical methods : advancing methods and applications

Published: February 12, 2024

Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration.

Journal: Molecules (Basel, Switzerland)

Published: August 31, 2023

Retraction Note: A candidate Chinese medicine preparation-Fructus Viticis Total Flavonoids inhibits stem-like characteristics of lung cancer stem-like cells.

Journal: BMC complementary medicine and therapies

Published: March 26, 2022

Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage.

Journal: International journal of biological sciences

Published: May 19, 2021

Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.

Journal: Oncology reports

Published: March 23, 2016